Kimberly-Clark to buy Kenvue in $48.7 billion deal


Huggies, manufactured by Kimberly-Clark and Band-Aid, manufactured by Kenvue.

Getty Images

Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at $48.7 billion that would create a consumer staples giant.

The deal is a combination of cash and stock. Shares of Kenvue surged 20% in premarket trading Monday, while shares of Kimberly-Clark plunged 14%.

The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol. It would include 10 billion-dollar brands, the companies said in a news release. The acquisition would be one of the largest on Wall Street this year.

The transaction is expected to close in the second half of 2026.

Kimberly-Clark Chairman and CEO Mike Hsu said in a statement that the companies share a “commitment to developing science and technology to provide extraordinary care.”

“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster,” Hsu said. “We have built the foundation and this transaction is a powerful next step in our journey.”

Kenvue, a portfolio of consumer health brands, spun out of Johnson & Johnson in May 2023. Since then, shares have fallen almost 35% from their initial public offering price. As of Friday’s close, Kenvue traded at about $14 per share for a market cap of roughly $27 billion.

Kenvue Chair Larry Merlo said in a statement that following a comprehensive strategic review, the board is “confident this combination represents the best path forward for our shareholders and all other stakeholders.”

Three Kenvue board members will join the Kimberly-Clark board upon the deal’s closing. Hsu will continue to serve as CEO.

The combined company would generate estimated 2025 annual net revenues of roughly $32 billion and adjusted EBITDA of approximately $7 billion, according to the release.

Kimberly-Clark and Kenvue expect about $1.9 billion in cost synergies from the transaction to be realized in the first three years following the deal’s close.


Related Posts

November home sales struggle as supply stalls

High home prices, stubbornly high mortgage rates and now less supply are all weighing on potential homebuyers. Sales of previously owned homes rose just 0.5% in November from October and…

Europe shows its commitment to Ukraine — but not unequivocally

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. An “unequivocal signal to Moscow” was how German Chancellor Friedrich…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

November home sales struggle as supply stalls

  • By admin
  • December 20, 2025
  • 0 views
November home sales struggle as supply stalls

What the chess world makes of Gukesh’s reign

  • By admin
  • December 20, 2025
  • 0 views
What the chess world makes of Gukesh’s reign

Canadian dollar steadies after mixed retail sales data

  • By admin
  • December 20, 2025
  • 0 views
Canadian dollar steadies after mixed retail sales data

Foreign prison officers exempted from new stricter visa rules

  • By admin
  • December 20, 2025
  • 0 views
Foreign prison officers exempted from new stricter visa rules

Want to get in shape in 2026? 3 smart and realistic fitness resolutions that help you see real results

  • By admin
  • December 19, 2025
  • 0 views
Want to get in shape in 2026? 3 smart and realistic fitness resolutions that help you see real results

To Improve Health, Design for Agency – The Health Care Blog

  • By admin
  • December 19, 2025
  • 8 views
To Improve Health, Design for Agency – The Health Care Blog